Propylene glycol accumulation associated with continuous infusion of lorazepam in pediatric intensive care patients

被引:39
作者
Chicella, M [1 ]
Jansen, P
Parthiban, A
Marlowe, KF
Bencsath, FA
Krueger, KP
Boerth, R
机构
[1] Auburn Univ, Clin Pharm Practice, Auburn, AL 36849 USA
[2] Auburn Univ, Dept Pharm Care Syst, Auburn, AL 36849 USA
[3] Univ S Alabama, Dept Pediat, Mobile, AL 36688 USA
[4] Univ S Alabama, Dept Internal Med, Mobile, AL 36688 USA
[5] Univ S Alabama, Dept Biochem & Mol Biol, Mobile, AL 36688 USA
[6] Univ S Alabama, Womens & Childrens Hosp, Mobile, AL 36688 USA
关键词
propylene glycol; lorazepam; sedation; children; serum lactate; serum osmolarity;
D O I
10.1097/00003246-200212000-00021
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: To determine if propylene glycol accumulates in children receiving continuous lorazepam infusion and, if accumulation occurs, to determine if it is associated with laboratory abnormalities. Design: Prospective study. Setting: A tertiary care pediatric intensive care unit. Patients: Eleven intubated pediatric intensive care patients receiving continuous lorazepam infusion for sedation. Interventions: Propylene glycol accumulation was determined by comparing concentrations at baseline, after 48 hrs, and at end of therapy. Laboratory abnormalities were determined by comparing serum lactate and osmolar gap at baseline, after 48 hrs, and at end of therapy. Correlation between the cumulative dose of lorazepam received and the propylene glycol concentration measured at the end of therapy was determined. Measurements and Main Results: Patients aged 1-15 months were studied. Lorazepam infusion rates ranged from 0.1 to 0.33 mg(.)kg(-1.)hr(-1) and lasted 3-14 days. Propylene glycol accumulated significantly in patients receiving continuous infusion of lorazepam. The propylene glycol concentration increased during the study from 86 +/- 93 mug/mL at baseline to 763 +/- 660 mug/mL at the end of the study (p =.038). A statistically significant correlation between the cumulative dose of lorazepam received and propylene glycol concentration at the end of therapy was demonstrated (r(2) =.65, p <.005). However, the propylene glycol accumulation was not associated with significant laboratory abnormalities. Neither serum lactate concentrations nor osmolar gap were significantly elevated over baseline. Conclusion: Propylene glycol accumulated significantly in pediatric intensive care patients receiving continuous lorazepam infusion, and propylene glycol concentration correlated with the cumulative lorazepam dose the patient received. However, significant laboratory abnormalities due to propylene glycol accumulation were not observed.
引用
收藏
页码:2752 / 2756
页数:5
相关论文
共 26 条
[11]  
Durbin C G Jr, 1994, New Horiz, V2, P64
[12]   HYPEROSMOLALITY INDUCED BY PROPYLENE-GLYCOL - A COMPLICATION OF SILVER SULFADIAZINE THERAPY [J].
FLIGNER, CL ;
JACK, R ;
TWIGGS, GA ;
RAISYS, VA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1985, 253 (11) :1606-1609
[13]  
GLASGOW AM, 1983, PEDIATRICS, V72, P353
[14]   OSMOL GAPS REVISITED - NORMAL VALUES AND LIMITATIONS [J].
HOFFMAN, RS ;
SMILKSTEIN, MJ ;
HOWLAND, MA ;
GOLDFRANK, LR .
JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY, 1993, 31 (01) :81-93
[15]   HYPER-OSMOLALITY IN THE BURN PATIENT - ANALYSIS OF AN OSMOLAL DISCREPANCY [J].
KULICK, MI ;
LEWIS, NS ;
BANSAL, V ;
WARPEHA, R .
JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 1980, 20 (03) :223-228
[16]   POLYETHYLENE-GLYCOL NEPHROTOXICITY SECONDARY TO PROLONGED HIGH-DOSE INTRAVENOUS LORAZEPAM [J].
LAINE, GA ;
HOSSAIN, SMH ;
SOLIS, RT ;
ADAMS, SC .
ANNALS OF PHARMACOTHERAPY, 1995, 29 (11) :1110-1114
[17]   PROPYLENE-GLYCOL TOXICITY FOLLOWING CONTINUOUS ETOMIDATE INFUSION FOR THE CONTROL OF REFRACTORY CEREBRAL EDEMA [J].
LEVY, ML ;
ARANDA, M ;
ZELMAN, V ;
GIANNOTTA, SL .
NEUROSURGERY, 1995, 37 (02) :363-369
[18]  
PRUITT AW, 1985, PEDIATRICS, V76, P635
[19]   Hyperlactatemia, increased osmolar gap, and renal dysfunction during continuous lorazepam infusion [J].
Reynolds, HN ;
Teiken, P ;
Regan, ME ;
Habashi, NM ;
Cottingham, C ;
McCunn, M ;
Scalea, TM .
CRITICAL CARE MEDICINE, 2000, 28 (05) :1631-1634
[20]   TOXICOLOGY, METABOLISM, AND BIOCHEMISTRY OF 1,2-PROPANEDIOL [J].
RUDDICK, JA .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1972, 21 (01) :102-&